Olivia Seraphim focuses her practice on health care regulatory, compliance and transactional matters spanning the health care services, life sciences and digital health sectors.
Positioned at the intersection of healthcare innovation and regulation, Olivia regularly advises clients on health care fraud and abuse issues, including Anti-Kickback Statute and Stark Law compliance, as well as licensure and certification, corporate practice of medicine and other learned professions, and health care data privacy matters under HIPAA and related laws, including with respect to artificial intelligence (AI). Olivia also assists in structuring and implementing compliance program infrastructure and advises on sales and marketing practices, strategic affiliations, acquisitions and other complex health care business arrangements. Olivia also has experience establishing and scaling physician practice and dental management services organizations.
Representative Experience
- Represented Eli Lilly and Company (NYSE: LLY) in its $1.4 billion acquisition of POINT Biopharma (Nasdaq: PNT), a radiopharmaceutical company.
- Represented Montagu Private Equity in its $700 million acquisition of the medical device components business from Johnson Matthey (LSE: JMAT).
- Represented Thoma Bravo in its acquisition of Circle Cardiovascular Imaging, a provider of cardiovascular imaging solutions.
View More
- Represented Waud Capital Partners-backed PharmAlliance in its acquisition of Biobridges, a drug development consulting business, from Soliant Health.
- Represented Thoma Bravo-backed Bluesight in its acquisition of Medacist, a provider of drug diversion monitoring.
- Represented FFL Partners in its investment in Johnson County Clin-Trials, a clinical research site platform serving pharmaceutical and biotechnology companies and contract research.
- Represented Eli Lilly and Company (NYSE: LLY) in its $1.075 billion sale of its BAQSIMI product, a nasally administered glucagon, to Amphastar Pharmaceuticals (Nasdaq: AMPH).
- Represented GTCR-backed Maravai Life Sciences (Nasdaq: MRVI) in its $240 million acquisition of MyChem, a provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets.
- Represented Vitruvian Partners in its acquisition of a majority stake in KCAS Bioanalytical and Biomarker Services, a contract research organization providing development testing services for the biotech, pharmaceutical and animal health industries.
- Represented Rite Aid Corporation and 119 of its affiliates in their prearranged chapter 11 cases in the U.S. Bankruptcy Court for the District of New Jersey.
- Represented Peak Rock Capital in its sale of Paragon Healthcare, Inc., a leading provider of infusion and other specialty pharmacy services, to Elevance Health, Inc.
- Represented One Equity Partners in its strategic investment of InfuCare Rx, a national provider of specialty infusion therapies.
- Represented Sun Capital Partners-backed Platinum Dermatology Partners in its acquisition of Skin & Cancer Associates, a network of physicians and providers of dermatology services.
- Represented TPG Growth in its partnership with Novant Health Enterprises to expand MedQuest Associates, a provider of diagnostic imaging facilities.
- Represented TCR, alongside Avryo Health Services, in its investment in 7to7 Dental, a dental service organization (DSO).
- Represented HGGC in its investment in Dentive, a DSO that provides management services to dental practices.
- Represented Knox Lane in its acquisition of All Star Healthcare Solutions, a health care staffing firm focused on the locum tenens markets.
- Represented Abry Partners-backed Millennium Trust Company in its acquisition of Benefit Resource, a provider of FSAs, HRAs, HSAs, commuter plans and COBRA administration services, from CIP Capital.
- Represented Thomas H. Lee Partners-backed IMO in its acquisition of Melax Technologies, a provider of natural language processing technology used to extract key information from biomedical textual data.
- Represented Waud Capital Partners in the sale of Integrated Practice Solutions, a provider of a practice management and electronic health record software platform, to PracticeTek.
- Represented Mercato Partners, as lead investor, in the $33 million Series B funding round in Paytient, a provider of health payment accounts (HPAs).
- Represented Thomas H. Lee Partners, as lead investor, in the $50 million Series C financing of Qventus, a provider of AI-powered software for care operations.
- Represented Vista Equity Partners in its strategic investment in iN2L, a provider of person-centered digital engagement solutions for the senior living market.
Education
-
J.D., The George Washington University Law School
B.A., University of California, Santa Cruz
cum laude
Admissions
-
District of Columbia
Languages
-
Spanish